Berberine Suggest an improvement to this article

Contents

  1. Background
  2. Anti-diabetic and glucoregulatory effects
  3. Weight gain and metabolic syndrome
  4. Cholesterol-reducing effects of berberine
    1. Animal evidence
    2. Human evidence
  5. Hypertension and congestive heart failure
  6. Anti-inflammatory and anti-cancer benefits in the gut and liver
  7. Brain and neurological disease
    1. Parkinson's disease and Huntington's disease
      1. Degeneration of dopaminergic neurons
    2. Multiple sclerosis
    3. Depression
    4. Bodyweight distribution and metabolism in polycystic ovarian syndrome
  8. Anti-aging effects
  9. Mechanisms of action
  10. Berberine versus metformin
    1. Effects on exercise adaptation: contrasting to metformin
  11. Berberine pharmacokinetics
  12. Toxicity profile and drug-drug interactions
  13. Conclusion
  14. Related resources
Berberine episodes Berberine news

Background

Berberine is an alkaloid compound present in the roots, stems, rhizomes, and bark of a variety of plants, including Californian poppy, goldenseal, cork tree, Chinese goldthread, Oregon grape, and several plants in the Berberis genus. It is also widely available as a dietary supplement. Berberine has a long history of use in the ancient and traditional medicine systems of India, China, and Persia. Research demonstrates that berberine may exert pharmacological effects against certain chronic health conditions such as cardiovascular disease, gastrointestinal disorders, neurodegenerative disease, depression, and metabolic dysfunction. Some of berberine's effects mirror those associated with metformin, an antihyperglycemic agent commonly used to treat type 2 diabetes. Preliminary research in animals also suggests that berberine may exert anti-aging properties and might be beneficial in combating aging-related diseases. However, the bulk of research involving berberine has been conducted in animals, with a paucity of trials in humans. This article provides an overview of the evidence demonstrating the beneficial health effects of berberine and compares and contrasts the compound's effects and mechanisms of action to those of metformin.

Anti-diabetic and glucoregulatory effects

"[Clinical] trials demonstrated that berberine was generally as effective as conventional antihyperglycemic agents, especially when participants engaged in lifestyle modifications to mitigate their diabetes." Click To Tweet

Oxidative stress and inflammation play critical roles in the pathogenesis of insulin resistance, diabetes, and their associated complications. Berberine has long been used as an effective treatment for diabetes in traditional Chinese medicine, likely due to its antioxidant and anti-inflammatory properties.[1]

Evidence from rodent studies suggests that berberine enhances pancreatic islet cell function, reduces LDL cholesterol, and ameliorates the harmful effects of diabetes on the kidneys.[2] [3] The results of human studies of berberine's effectiveness against diabetes have been mixed, however.

A randomized clinical trial involving 97 people with diabetes compared the effects of berberine, metformin, and rosiglitazone for two months. Berberine (1 gram per day) lowered the participants' fasting blood glucose, hemoglobin (Hb)A1c (a measure of long-term blood glucose control), triglycerides, and insulin levels. The effects of berberine on blood glucose levels (26 percent reduction) and HbA1c (18 percent reduction) were comparable to those achieved with metformin and rosiglitazone.[4]

A meta-analysis of 14 clinical trials involving more than 1,000 people with diabetes found that the trials differed markedly in terms of design, dose, and duration.[1] Some of the trials employed multiple strategies to mitigate diabetes in conjunction with berberine, including lifestyle modifications, antihyperglycemic agents (such as metformin, glipizide, or rosiglitazone), and aspirin. Berberine doses ranged from 0.5 to 1.5 grams daily, provided in two or three doses. Trial duration ranged from eight to 24 weeks. The trials demonstrated that berberine was generally as effective as conventional antihyperglycemic agents, especially when participants engaged in lifestyle modifications to mitigate their diabetes. Berberine potentiated the effects of antihyperglycemic agents when used in conjunction with the drugs. Few adverse effects were noted other than mild gastrointestinal discomfort. The authors of the analysis conceded that the trials reviewed in the analysis were of poor quality and advocated for better-designed trials in the future.[1]

A more recent meta-analysis of studies involving 2,500 participants with diabetes provides even stronger evidence of berberines' metabolic benefits. Researchers found that berberine supplementation with lifestyle modifications reduced HbA1c, normalized blood lipids (i.e., cholesterol, triglycerides), and lowered blood pressure better than lifestyle modifications alone and better than placebo supplementation.[5]

Weight gain and metabolic syndrome

Excess body weight contributes to a wide range of health disorders, including metabolic syndrome. Findings from a randomized controlled trial demonstrate the efficacy of berberine supplementation in preventing weight gain and metabolic syndrome among patients taking antipsychotic medications, which cause predictable weight gain, glucose dysfunction, and dyslipidemia, contributing to higher rates of cardiovascular disease in people with severe neuropsychiatric illnesses such as schizophrenia and bipolar disorder. The participants took a placebo or 600 or 900 milligrams of berberine per day for 12 weeks. Participants taking 600 milligrams of berberine per day had better cholesterol and glucose levels at the end of 12 weeks and lost 2.4 pounds more than the placebo group. Participants taking the higher dose (900 milligrams) exhibited similar improvements and saw these improvements faster after just eight weeks of supplementation.[6]

Cholesterol-reducing effects of berberine

Statins are typically the first drug of choice for improving lipid profiles, especially among people who are at risk for cardiovascular disease. However, as many as 10 to 20 percent of people taking the drugs experience complications, including myopathy (muscle damage) or liver damage. Statins lower blood cholesterol levels by blocking the production of an enzyme in the liver called hydroxy-methylglutaryl-coenzyme A reductase, commonly referred to as HMG-CoA reductase. Berberine also lowers blood cholesterol, but the mechanisms by which it elicits these effects (such as regulation of proteins involved in cholesterol metabolism) differ from those of statins. Interestingly, berberine use in conjunction with statin therapy has been more effective than either compound alone.[7]

Animal evidence

Multiple studies in rabbits and rats fed obesity-promoting diets demonstrate that berberine reduces serum total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides and increases high-density lipoprotein (HDL) cholesterol. Evidence suggests berberine also modulates factors involved in the pathogenesis of atherosclerosis.[8]

Human evidence

Human studies demonstrate similar effects. A clinical study assessed the effects of 500 milligrams of berberine versus a placebo taken twice daily for three months in a double-blind, placebo-controlled trial involving 144 people. The participants who took the berberine lost weight and saw improvements in their total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol compared to the placebo group.[9] A separate study involving 228 people who had high cholesterol but were unable or unwilling to take statins investigated the effects of berberine, ezetimibe (a cholesterol-lowering drug), or the two compounds together in modulating cholesterol levels. The findings indicated that a nutraceutical product containing berberine, policosanols, and red yeast rice reduced LDL cholesterol by nearly 32 percent, while ezetimibe reduced it by approximately 25 percent. In addition, berberine elicited fewer side effects.[10]

A larger clinical trial with more than 1,380 participants who did not have diabetes found that taking a proprietary supplement that included berberine for eight weeks increased HDL cholesterol and reduced non-HDL cholesterol, triglycerides, waist circumference, and blood pressure, all biomarkers used to diagnose metabolic syndrome. Overall, participants who met the criteria for metabolic syndrome at the end of the trial significantly decreased.[11]

"Participants who took berberine lost weight and saw improvements in their total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol, compared to the placebo group." Click To Tweet

Hypertension and congestive heart failure

Berberine exhibits pharmacological action in a variety of chronic diseases.

Hypertension damages blood vessels and promotes kidney failure. In a rodent model of hypertension, berberine administration delayed the onset and reduced the severity of hypertension by reducing angiotensin II and aldosterone (hormones that elevate blood pressure). The compound also reduced levels of proinflammatory cytokines, such as interleukin (IL)-6, IL-17, and IL-23, which drive blood vessel and kidney damage.[12] Similarly, berberine promoted aortic relaxation in isolated mice aortas, induced relaxation of mice vascular smooth muscle cells in culture, and lowered systemic blood pressure in hypertensive mice. These effects were attributed to the suppression of the transient receptor potential vanilloid 4 channel – a protein that plays roles in vascular function, among others.[13]

Congestive heart failure is typically described as the end stage of heart disease. The potential role for berberine in treating congestive heart failure was observed in a rat model, when high doses of the compound improved several markers of cardiac function, including left ventricular end-diastolic pressure – the amount of blood in the heart's left ventricle and a measure of the risk of subsequent heart failure.[14]

Clinical trials are needed to fully elucidate the cardiovascular benefits of berberine in humans.

Anti-inflammatory and anti-cancer benefits in the gut and liver

"In a randomized, double-blind placebo-controlled clinical trial involving people with IBS, berberine reduced diarrhea frequency, abdominal pain, and the urgent need for defecation." Click To Tweet

Berberine may have beneficial effects in multiple tissues in the gut, especially the liver and intestine. However, much of the data demonstrating these effects come from cell culture studies and may or may not have applicability to humans.

In the liver, cell culture studies demonstrate that the compound inhibits the proliferation and growth of hepatic stellate cells, the primary driver in the development of liver fibrosis.[15] A rodent study in which rats received berberine at 50, 100, or 200 milligrams per kilogram of body weight (mg/kg/bw) per day demonstrated that tissue changes such as steatosis, necrosis, and myofibroblast proliferation, as well as several markers of liver dysfunction, decreased when compared to controls.[16]

Other cell culture studies demonstrate that berberine may provide protection against non-alcoholic fatty liver disease, or NAFLD, a syndrome that encompasses multiple states of liver dysfunction, including steatosis, nonalcoholic steatohepatitis, and cirrhosis. Multiple mechanisms associated with this protective effect have been identified and center on aspects of improved glucose and lipid metabolism, reversed methylation states of genes that participate in lipid metabolism, and enhanced antioxidant capacity of liver cells.[17] [18] [19] [20]

Clinical research needs to confirm whether berberine has beneficial effects on the liver in humans.

In the intestine, berberine appears to be beneficial in reducing factors that drive inflammatory conditions. In cell culture studies, berberine reduced pro-inflammatory cytokines and apoptosis in the gut – two hallmarks of inflammatory bowel disease.[21] The compound also improved symptoms associated with irritable bowel syndrome, or IBS, in humans. In a randomized, double-blind placebo-controlled clinical trial involving 132 people with IBS who took 400 milligrams of berberine or a placebo twice daily for eight weeks, participants experienced reduced diarrhea frequency, abdominal pain, and the urgent need for defecation. Interestingly, the participants also reported improvements in quality of life and reduced levels of depression, a common feature among people with IBS.[22]

Additional clinical research is needed to confirm whether berberine has beneficial effects on the intestine in humans.

Brain and neurological disease

Berberine acts on multiple pathways and processes that promote neuroprotection and overall central nervous system health.

Parkinson's disease and Huntington's disease

Berberine elicits variable effects on the pathogenic processes involved in neurodegenerative disorders such as Parkinson's disease and Huntington's disease. For example, daily oral administration of berberine at 20, 50, or 80 milligrams per kilogram of body weight (mg/kg/bw) prevented damage to dopaminergic neurons and improved short-term memory in a mouse model of Parkinson's disease.[23] Similarly, in a transgenic mouse model of Huntington's disease, oral berberine (40 mg/kg/bw) per day increased autophagy, which, in turn, promoted cellular degradation of mutant huntingtin, the protein implicated in the pathogenesis of the disease.[24] A mouse study that investigated the effects of berberine on neuropathic pain associated with diabetes demonstrated that berberine suppressed microglia and astrocyte activation and inhibited expression of proinflammatory cytokines that drive neuropathic pain.[25]

Degeneration of dopaminergic neurons

Berberine promoted the degeneration of dopaminergic neurons in cell cultures and in a rat model of Parkinson's disease and reduced dopamine levels in the substantia nigra, the region of the brain most affected by the disease.[26] [27] The authors of an extensive review of the effects of berberine on the neurological system found that berberine generally had favorable effects, but expressed concerns that dose- and species-dependent differences in berberine metabolism could alter some findings.[28]

Multiple sclerosis

Preclinical evidence suggests that berberine shows promise in treating the clinical symptoms associated with multiple sclerosis, or MS, a type of autoimmune disease that affects the central nervous system. In a mouse model of the disease, oral berberine administration (30 mg/kg/bw per day) reduced several of the pathological hallmarks associated with MS, including blood-brain barrier permeability and factors that drive the degradation of myelin.[29] [29]

Depression

The antidepressant effects of berberine have been observed in mice. In particular, studies demonstrate that berberine administration modulates levels of serotonin, dopamine, and norepinephrine – neurotransmitters that influence mood – by increasing their uptake in the brain.[30] [31] A mouse study demonstrated that oral berberine (50 or 100 mg/kg/bw per day) reversed the depression-inducing effects of corticosterone injection by upregulating hippocampal synthesis of brain-derived neurotrophic factor – a type of protein that acts on neurons in the central and peripheral nervous systems and may be important for the antidepressant response.[32] [33]

Clinical trials are needed to fully elucidate the neurological benefits of berberine in humans.

Bodyweight distribution and metabolism in polycystic ovarian syndrome

Polycystic ovarian syndrome, or PCOS, is a hormonal disorder characterized by menstrual irregularities, metabolic dysfunction, excess hair growth, acne, and obesity. The condition affects as many as 10 percent of women of reproductive age.[34] Women with PCOS produce abnormal levels of androgens (male sex hormones) and often experience infertility.

Findings from an analysis of five studies involving more than 1,000 women found that berberine may be useful in managing PCOS. The studies revealed that women who took berberine experienced adipose tissue redistribution. In turn, the women's visceral fat mass decreased, even in the absence of weight loss. The women's insulin sensitivity and lipid profiles improved, too. Importantly, berberine improved insulin sensitivity in the women's theca cells, which are specialized endocrine cells in the ovaries that play roles in fertility. Consequently, the women's ovulation rate improved, with reciprocal improvements in live birth rates.[35]

It is noteworthy that the formulations used in the five studies varied considerably. Two studies administered 500 milligrams of berberine hydrochloride three times per day; one administered 588 milligrams of Berberis aristata extract twice daily; one gave 500 milligrams of berberine plus 3 milligrams of monacolins (a type of statin) once daily; and one provided 1.5 grams of berberine once daily.[35]

Anti-aging effects

Berberine exerts anti-aging effects in cell culture, insect, and rodent studies. Cell culture studies demonstrate that berberine attenuates cellular senescence, a process of deterioration that occurs with age.[36] Senescent cells can no longer replicate (divide) and are not metabolically active. They often release inflammatory cytokines, which can promote damage to neighboring healthy cells.

Berberine demonstrates anti-aging effects in skin cell culture studies due to its inhibitory action on the activity of matrix metalloproteinase-1 and matrix metalloproteinase-9, enzymes that play roles in ultraviolet light-induced skin damage and skin cancer.[37] Conversely, the compound promotes the activity of procollagen, a precursor to collagen and a critical player in skin integrity.[38]

Studies in insects demonstrate that berberine extends lifespan and healthspan. Fruit flies given berberine lived 27 percent longer and were 39 percent more physically active than a control group.[39] A different study found that berberine ameliorated the harmful, pro-aging effects of heat on fruit flies[40]

A multiple-model study of the effects of berberine on aging found that the compound improved several aspects of aging in human lung fibroblasts by promoting the cells' progression through the cell growth cycle. The cells' replicative capacity was longer, and their overall shape was more similar to younger cells. The lifespan of naturally-aged mice that were given berberine was nearly 17 percent longer and nearly 50 percent longer among chemotherapy-treated mice given berberine. In addition, the mice showed improvements in healthspan, fur density, and behavior.[41]

These data in cell culture, fruit flies, and rodents indicate that berberine may positively influence aging. However, whether berberine affects the aging process in humans is unclear.

Mechanisms of action

Multiple mechanisms of action have been proposed as drivers of the beneficial effects of berberine. These mechanisms capitalize on berberine's capacity to reduce oxidative stress via activation or inhibition of multiple cellular signaling pathways. Some of these pathways are described here.

The primary mechanism associated with berberine's effects centers on its activation of adenosine monophosphate-activated protein kinase, or AMPK, in multiple cell types, including endothelium, smooth muscle, cardiomyocytes, cancer cells, pancreatic beta cells, hepatocytes, macrophages, and adipocytes.[42] AMPK serves as a master regulator of cellular energy homeostasis by sensing cellular energy deficits. Its activation influences gene expression and inhibits cellular processes that drive oxidative stress.

Berberine also activates p38, an enzyme that participates in the body's stress response.[43] The co-activation of AMPK and p38 switches on the activity of Nrf2, a cellular protein that regulates the expression of antioxidant and stress response proteins. Nrf2 is an element of the Keap1-Nrf2-ARE biological pathway, which activates the transcription of cytoprotective proteins that protect against oxidative stress due to injury and inflammation.[44]

Berberine inhibits the activity of I-Kappa B kinase and Rho GTPase, enzymes that promote inflammation.[43] Inhibition of these two enzymes deactivates NF-kappa B, downregulating a cascade of pro-inflammatory events.

Biosynthesis of berberine. Source: Wikipedia

Berberine versus metformin

"Berberine and metformin differ markedly in their chemical structures and bioavailability, but they share many features in their activities against type 2 diabetes, cardiovascular disease, cancer, and inflammation." Click To Tweet

Some of berberine's effects mirror those associated with metformin, an antihyperglycemic agent commonly used to treat type 2 diabetes. Some evidence suggests that metformin may modulate the aging processes to improve healthspan and extend lifespan in multiple species, including flies, worms, and rodents, with limited evidence in humans. In addition, evidence suggests that metformin may prevent cognitive losses, improve mental health status, and reduce the risk of cancer. However, metformin may inhibit exercise-induced health benefits, especially regarding muscle mitochondrial adaptations and muscle hypertrophy.

The mechanisms by which metformin exerts its effects are not fully understood, but evidence suggests that metformin activates AMPK and inhibits mTOR, pathways involved in cellular energy and antioxidant responses.

Metformin and berberine differ markedly in their chemical structures and bioavailability, but they share many features in their activities against type 2 diabetes, cardiovascular disease, cancer, and inflammation.[45] Whereas evidence indicates that metformin blunts the beneficial effects of exercise, the evidence regarding berberine and exercise is somewhat mixed. Both compounds have low toxicity but are contraindicated in some (but differing) circumstances.

Effects on exercise adaptation: contrasting to metformin

Like berberine, metformin activates AMPK and other cellular pathways that reduce oxidative stress and damage. Evidence suggests that metformin inhibits mitochondrial adaptations and improvements in cardiorespiratory fitness and diminishes whole-body insulin sensitivity after aerobic exercise.[46] Due to berberine's effects on AMPK activity and the subsequent reduction in reactive species, some researchers have posited that berberine may similarly blunt the effects of exercise.[47] However, an intervention study that investigated the effects of berberine and circuit training in sedentary, overweight men found that berberine enhanced the effects of exercise.[48] Similarly, berberine potentiated the effects of aerobic exercise in diabetic rats as evidenced by higher levels of antioxidant enzymes in the animals' pancreatic tissues.[49] Exercise to exhaustion can induce damage to the heart muscle, but berberine attenuates the harmful effects of exhaustion-induced heart damage in mice, likely via its inhibitory effects on the release of reactive oxygen species and apoptosis of cardiomyocytes.[50]

More clinical studies involving large groups of participants are needed to determine the effects of berberine on exercise-induced health benefits.

Berberine pharmacokinetics

Berberine undergoes extensive metabolism in the intestine due to active efflux of the compound via p-glycoproteins, a class of transporters involved in the clearance of xenobiotic substances, such as drugs, toxins, and polyphenols.[8] Consequently, oral berberine demonstrates notably poor bioavailability – as low as 1 percent or less – in rodent studies.[51] [52] However, the use of alternate delivery systems of berberine such as mucoadhesive microparticle formulation, anhydrous reverse micelle microemulsion, or oral microemulsion substantially increases the compound's bioavailability and subsequent plasma concentrations. [53] [54] [55]

Following absorption in the intestinal mucosa, berberine undergoes biotransformation in the liver via phase 1 and phase 2 metabolism to yield its primary metabolites, berberrubine, thalifendine, and jatrorrhizine.[56] The principal enzymes involved in phase 1 metabolism of berberine are the cytochrome P450, or CYP, enzymes, specifically CYP2D6.[8] Genetic polymorphisms that influence the expression of CYP2D6 subsequently influence berberine metabolism and should be taken into consideration when determining dose.

Interestingly, despite berberine's poor oral bioavailability and resultant low plasma concentration, it is found widely distributed in the body's tissues following ingestion, especially in the liver, kidneys, muscles, lungs, and brain. A rodent study reconciled this anomaly by demonstrating that gut microbes convert berberine to dihydroberberine, a more absorbable form of the compound (fivefold greater).[57] A study in humans indicated that berberine exhibited differential metabolism due to variations in gut microbial makeup related to dietary intake. One study demonstrated that plasma berberine concentrations were more than twofold higher among young African males than young Asian males, suggesting that personalized approaches to dosing berberine may be called for.[58]. The majority of berberine is excreted in feces, bile, and urine within 48 hours of administration.

Toxicity profile and drug-drug interactions

Berberine is well-tolerated and has low toxicity in rodents. However, the mode of delivery markedly influences the dose at which berberine is lethal. Whereas intragastric delivery is non-lethal, intravenous and intraperitoneal delivery can achieve lethal levels.[59] The most commonly reported negative effects of berberine in humans are diarrhea and constipation, observed with doses of 500 milligrams per day, especially when used in conjunction with anti-hyperglycemic agents. A dose of 300 milligrams given three times daily reduced the risk of gastrointestinal distress.[60] [61]

Berberine impairs the activity of enzymes that metabolize a variety of drugs, markedly increasing the bioavailability of ketoconazole (an antifungal drug), cyclosporine (an immunosuppressant), digoxin (an antiarrhythmic), and metformin.[62] [63] [64] The increased bioavailability of metformin when used with berberine raises particular concerns due to the compounds' capacity to decrease blood glucose levels. Caution is advised when taking the two together.

Conversely, findings from rodent and human trials suggest that berberine dampens the harmful effects of some pharmaceuticals, including cisplatin, isoniazid, bleomycin, doxorubicin, non-steroidal anti-inflammatory drugs, and others.[65] [66] [67] [68]

Conclusion

Berberine is a plant-based bioactive compound found in various plants and is widely available as a dietary supplement. Evidence from animal and human studies suggests that berberine is beneficial for improving lipid profiles, enhancing blood glucose regulation, and combating aging-related diseases, such as cardiovascular disease, gastrointestinal disorders, neurological disorders, and type 2 diabetes. Berberine undergoes extensive metabolism in the gut, has notably poor bioavailability, and demonstrates a generally favorable safety profile. Berberine and metformin differ markedly in their chemical structures and bioavailability, but they share many features in terms of their effects on chronic diseases. Furthermore, the two compounds work via many of the same mechanisms, such as activation of AMPK and various cellular energy and antioxidant pathways. Conversely, the mechanisms that drive berberine's lipid-lowering effects, such as regulating various proteins involved in cholesterol metabolism, differ from the mechanisms by which statins work. Although berberine shows promise as a potential therapy for various health conditions, clinical research is needed to confirm the compound's proposed effects in humans.

  1. ^ a b c Dong, Hui; Wang, Nan; Zhao, Li; Lu, Fuer (2012). Berberine In The Treatment Of Type 2 Diabetes Mellitus: A Systemic Review And Meta-Analysis Evidence-Based Complementary And Alternative Medicine 2012, .
  2. ^ Chueh, Wei-Han; Lin, Jin-Yuarn (2011). Berberine, An Isoquinoline Alkaloid In Herbal Plants, Protects Pancreatic Islets And Serum Lipids In Nonobese Diabetic Mice Journal Of Agricultural And Food Chemistry 59, 14.
  3. ^ Lan, Tian; Shen, Xiaoyan; Liu, Peiqing; Liu, Weihua; Xie, Xi; Jiang, Qin, et al. (2010). Berberine Ameliorates Renal Injury In Diabetic C57BL/6 Mice: Involvement Of Suppression Of SphK–S1P Signaling Pathway Archives Of Biochemistry And Biophysics 502, 2.
  4. ^ Zhou, Zheng-Xian; Song, Dan-Qing; Wang, Yue-Ming; Pan, Huai-Ning; Kong, Wei-Jia; Jiang, Jian-Dong, et al. (2010). Berberine Lowers Blood Glucose In Type 2 Diabetes Mellitus Patients Through Increasing Insulin Receptor Expression Metabolism 59, 2.
  5. ^ Yan, Ziyou; Zheng, Wenjie; Fan, Jinping; Sun, Guoli; Lan, Jiarong; Zhao, Yanyun, et al. (2015). Meta-analysis Of The Effect And Safety Of Berberine In The Treatment Of Type 2 Diabetes Mellitus, Hyperlipemia And Hypertension Journal Of Ethnopharmacology 161, .
  6. ^ Qiu, Yuying; Zhang, Jing; Zhang, Yonghui; Zhao, Yongping; Jia, Qiong; Li, Jie, et al. (2021). The Effect Of Berberine Adjunctive Treatment On Glycolipid Metabolism In Patients With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Psychiatry Research 300, .
  7. ^ Kong, Wei-Jia; Wei, Jin; Zuo, Zeng-Yan; Wang, Yue-Ming; Song, Dan-Qing; You, Xue-Fu, et al. (2008). Combination Of Simvastatin With Berberine Improves The Lipid-Lowering Efficacy Metabolism 57, 8.
  8. ^ a b c Imenshahidi, Mohsen; Hosseinzadeh, Hossein (2016). Berberis Vulgarisand Berberine: An Update Review Phytotherapy Research 30, 11.
  9. ^ D'Angelo, Angela; Bianchi, Lucio; Romano, Davide; Derosa, Giuseppe; Maffioli, Pamela; Bonaventura, Aldo (2013). Effects Of Berberine On Lipid Profile In Subjects With Low Cardiovascular Risk Expert Opinion On Biological Therapy 13, 4.
  10. ^ Pisciotta L; Bellocchio A; Bertolini S (2012). Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids Health Dis 11, .
  11. ^ Giudice, Renata; Trimarco, Bruno; De Simone, Giovanni; Trimarco, Valentina; Izzo, Raffaele; Chinali, Marcello, et al. (2010). Effects Of Nutraceuticals On Prevalence Of Metabolic Syndrome And On Calculated Framingham Risk Score In Individuals With Dyslipidemia Journal Of Hypertension 28, 7.
  12. ^ Guo, Zhentao; Sun, Hongri; Zhang, Huamin; Zhang, Yanfeng (2015). Anti-hypertensive And Renoprotective Effects Of Berberine In Spontaneously Hypertensive Rats Clinical And Experimental Hypertension 37, 4.
  13. ^ Wang, Jie; Guo, Tao; Peng, Qi-Sheng; Yue, Shou-Wei; Wang, Shuang-Xi (2015). Berberine Via Suppression Of Transient Receptor Potential Vanilloid 4 Channel Improves Vascular Stiffness In Mice Journal Of Cellular And Molecular Medicine 19, 11.
  14. ^ Zhang XD; Ren HM; Liu L (2008). [Effects of different dose berberine on hemodynamic parameters and [Ca2+]i of cardiac myocytes of diastolic heart failure rat model]. Zhongguo Zhong Yao Za Zhi 33, 7.
  15. ^ Sun, Xu; Zhang, Xiaodong; Hu, Hui; Lu, Yina; Chen, Jie; Yasuda, Kazuki, et al. (2009). Berberine Inhibits Hepatic Stellate Cell Proliferation And Prevents Experimental Liver Fibrosis Biological And Pharmaceutical Bulletin 32, 9.
  16. ^ Zhang, Ben-Jian; Xu, Dan; Guo, Yu; Ping, Jie; Chen, Liao-bin; Wang, Hui (2008). Protection By And Anti-Oxidant Mechanism Of Berberine Against Rat Liver Fibrosis Induced By Multiple Hepatotoxic Factors Clinical And Experimental Pharmacology And Physiology 35, 3.
  17. ^ Chang X; Yan H; Fei J; Jiang M; Zhu H; Lu D, et al. (2010). Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res 51, 9.
  18. ^ Xie, Zuoquan; Li, Houkai; Wang, Ke; Lin, Jingchao; Wang, Qi; Zhao, Guoping, et al. (2010). Analysis Of Transcriptome And Metabolome Profiles Alterations In Fatty Liver Induced By High-Fat Diet In Rat Metabolism 59, 4.
  19. ^ Yang, Qin-he; Hu, Si-ping; Zhang, Yu-pei; Xie, Wei-ning; Li, Na; Ji, Gui-yuan, et al. (2011). Effect Of Berberine On Expressions Of Uncoupling Protein-2 mRNA And Protein In Hepatic Tissue Of Non-Alcoholic Fatty Liver Disease In Rats Chinese Journal Of Integrative Medicine 17, 3.
  20. ^ Xing, Lian-Jun; Zhang, Li; Liu, Tao; Hua, Yong-Qiang; Zheng, Pei-Yong; Ji, Guang (2011). Berberine Reducing Insulin Resistance By Up-Regulating IRS-2 mRNA Expression In Nonalcoholic Fatty Liver Disease (NAFLD) Rat Liver European Journal Of Pharmacology 668, 3.
  21. ^ Hao, Xianhua; Yao, Anlong; Gong, Jianfeng; Zhu, Weiming; Li, Ning; Li, Jieshou (2011). Berberine Ameliorates Pro-inflammatory Cytokine-Induced Endoplasmic Reticulum Stress In Human Intestinal Epithelial Cells In Vitro Inflammation 35, 3.
  22. ^ Fichna, Jakub; Chen, Chunqiu; Tao, Chunhua; Liu, Zhongchen; Lu, Meiling; Pan, Qiuhui, et al. (2015). A Randomized Clinical Trial Of Berberine Hydrochloride In Patients With Diarrhea-Predominant Irritable Bowel Syndrome Phytotherapy Research 29, 11.
  23. ^ Kim, Mia; Cho, Ki-Ho; Shin, Mal-Soon; Lee, Jae-Min; Cho, Han-Sam; Kim, Chang-Ju, et al. (2014). Berberine Prevents Nigrostriatal Dopaminergic Neuronal Loss And Suppresses Hippocampal Apoptosis In Mice With Parkinson’s Disease International Journal Of Molecular Medicine 33, 4.
  24. ^ Jiang, Wenxiao; Wei, Wenjie; Gaertig, Marta A.; Li, Shihua; Li, Xiao-Jiang (2015). Therapeutic Effect Of Berberine On Huntington’s Disease Transgenic Mouse Model Plos One 10, 7.
  25. ^ Liu, Mei; Gao, Linlin; Zhang, Na (2019). Berberine Reduces Neuroglia Activation And Inflammation In Streptozotocin-Induced Diabetic Mice International Journal Of Immunopathology And Pharmacology 33, .
  26. ^ Shin, Keon Sung; Choi, Hyun Sook; Zhao, Ting Ting; Suh, Kwang Hoon; Kwon, Ik Hyun; Choi, Soon Ok, et al. (2013). Neurotoxic Effects Of Berberine On Long-Term l-DOPA Administration In 6-Hydroxydopamine-Lesioned Rat Model Of Parkinson’s Disease Archives Of Pharmacal Research 36, 6.
  27. ^ Kwon, Ik Hyun; Choi, Hyun Sook; Shin, Kun Seong; Lee, Byung Koo; Lee, Chong Kil; Hwang, Bang Yeon, et al. (2010). Effects Of Berberine On 6-Hydroxydopamine-Induced Neurotoxicity In PC12 Cells And A Rat Model Of Parkinson's Disease Neuroscience Letters 486, 1.
  28. ^ Jiang, WenXiao; Li, ShiHua; Li, XiaoJiang (2015). Therapeutic Potential Of Berberine Against Neurodegenerative Diseases Science China Life Sciences 58, 6.
  29. ^ a b Jiang, Ying; Wu, Aiming; Zhu, Cansheng; Pi, Rongbiao; Chen, Shaoqiong; Liu, Yingying, et al. (2013). The Protective Effect Of Berberine Against Neuronal Damage By Inhibiting Matrix Metalloproteinase-9 And Laminin Degradation In Experimental Autoimmune Encephalomyelitis Neurological Research 35, 4.
  30. ^ Dhir, Ashish; Kulkarni, Shrinivas K. (2008). On The Mechanism Of Antidepressant-Like Action Of Berberine Chloride European Journal Of Pharmacology 589, 1-3.
  31. ^ Sun, Siyuan; Wang, Kai; Lei, Hongmei; Li, Liping; Tu, Meijuan; Zeng, Su, et al. (2014). Inhibition Of Organic Cation Transporter 2 And 3 May Be Involved In The Mechanism Of The Antidepressant-Like Action Of Berberine Progress In Neuro-Psychopharmacology And Biological Psychiatry 49, .
  32. ^ Ma, Li-Gang; Li, Yu-Cheng; Shen, Ji-duo; Hu, Chun-yue; Pei, Yang-yi; Jin, Shuang-li, et al. (2016). Berberine Up-Regulates The BDNF Expression In Hippocampus And Attenuates Corticosterone-Induced Depressive-Like Behavior In Mice Neuroscience Letters 614, .
  33. ^ Lee, Bun-Hee; Kim, Yong-Ku (2010). The Roles Of BDNF In The Pathophysiology Of Major Depression And In Antidepressant Treatment Psychiatry Investigation 7, 4.
  34. ^ Escobar-Morreale, Hctor F (2018). Polycystic Ovary Syndrome: Definition, Aetiology, Diagnosis And Treatment Nature Reviews Endocrinology 14, 5.
  35. ^ a b Perna, Simone; Rondanelli, Mariangela; Peroni, Gabriella; Gasparri, Clara; Infantino, Vittoria; Spadaccini, Daniele, et al. (2020). Polycystic Ovary Syndrome Management: A Review Of The Possible Amazing Role Of Berberine Archives Of Gynecology And Obstetrics 301, 1.
  36. ^ Xu Z; Feng W; Shen Q; Yu N; Yu K; Wang S, et al. (2017). Rhizoma Coptidis and Berberine as a Natural Drug to Combat Aging and Aging-Related Diseases via Anti-Oxidation and AMPK Activation. Aging Dis 8, 6.
  37. ^ Kim, Sangmin; Kim, Yoonkyung; Kim, Ji Eun; Cho, Kwang Hyun; Chung, Jin Ho (2008). Berberine Inhibits TPA-induced MMP-9 And IL-6 Expression In Normal Human Keratinocytes Phytomedicine 15, 5.
  38. ^ Kim, Sangmin; Chung, Jin Ho (2008). Berberine Prevents UV-induced MMP-1 And Reduction Of Type I Procollagen Expression In Human Dermal Fibroblasts Phytomedicine 15, 9.
  39. ^ Navrotskaya, V. V.; Oxenkrug, G.; Vorobyova, L. I.; Summergrad, P. (2012). Berberine Prolongs Life Span And Stimulates Locomotor Activity Of <i>Drosophila Melanogaster</I> American Journal Of Plant Sciences 03, 07.
  40. ^ Navrotskaya, Valeriya; Oxenkrug, Gregory; Vorobyova, Lyudmila; Summergrad, Paul (2014). Berberine Attenuated Aging-Accelerating Effect Of High Temperature In Drosophila Model American Journal Of Plant Sciences 05, 03.
  41. ^ An, Yongpan; He, Jinzhao; Huang, Boyue; Zhu, Jie; Gao, Miaomiao; Zhang, Shun, et al. (2019). Berberine Ameliorates Cellular Senescence And Extends The Lifespan Of Mice Via Regulating P16 And Cyclin Protein Expression Aging Cell 19, 1.
  42. ^ Zhou G; Myers R; Li Y; Chen Y; Shen X; Fenyk-Melody J, et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108, 8.
  43. ^ a b Cicero, Arrigo F. G.; Baggioni, Alessandra (2016). Berberine And Its Role In Chronic Disease Advances In Experimental Medicine And Biology , .
  44. ^ Baird, Liam; Dinkova-Kostova, Albena T (2011). The Cytoprotective Role Of The Keap1–Nrf2 Pathway Archives Of Toxicology 85, 4.
  45. ^ Luo, Zhijun; Wang, Haoran; Zhu, Chen; Ying, Ying; Luo, Lingyu; Huang, Deqiang (2017). Metformin And Berberine, Two Versatile Drugs In Treatment Of Common Metabolic Diseases Oncotarget 9, 11.
  46. ^ Reid, Justin J.; Castor, William M.; Musci, Robert V.; Safairad, Oscar D.; Biela, Laurie M.; Bailey, Susan M., et al. (2018). Metformin Inhibits Mitochondrial Adaptations To Aerobic Exercise Training In Older Adults Aging Cell 18, 1.
  47. ^ Calbet, J.A.L; Morales-Alamo, David (2016). AMPK Signaling In Skeletal Muscle During Exercise: Role Of Reactive Oxygen And Nitrogen Species Free Radical Biology And Medicine 98, .
  48. ^ DOI: 10.22100/ijhs.v5i2.610
  49. ^ DOI: 10.18502/ijdo.v11i4.2882
  50. ^ Wang YW; Li XD; Sun MJ; Liu ZP; Liu SW (2019). [Protective effects of berberine against exhaustion exercise induced myocardial injury in rats]. Zhonghua Xin Xue Guan Bing Za Zhi 47, 8.
  51. ^ Chen, Wei; Miao, Yu-Qiang; Fan, Dong-Jiao; Yang, Shen-Shen; Lin, Xia; Meng, Ling-Kuo, et al. (2011). Bioavailability Study Of Berberine And The Enhancing Effects Of TPGS On Intestinal Absorption In Rats AAPS PharmSciTech 12, 2.
  52. ^ Xie, Hong-Guang; Lai, Li; Wang, Qiong; Liu, Chang-Xiao; Wang, Guang-Ji; Hao, Haiping, et al. (2010). Extensive Intestinal First-Pass Elimination And Predominant Hepatic Distribution Of Berberine Explain Its Low Plasma Levels In Rats Drug Metabolism And Disposition 38, 10.
  53. ^ Patel, Apurva R.; Doddapaneni, Ravi; Somagoni, Jaganmohan; Singh, Mandip; Godugu, Chandraiah (2014). Approaches To Improve The Oral Bioavailability And Effects Of Novel Anticancer Drugs Berberine And Betulinic Acid Plos One 9, 3.
  54. ^ DOI: 10.1691/ph.2008.8018
  55. ^ Wang, Ting; Wang, Ning; Song, Hui; Xi, Xiaonan; Wang, JianAn; Hao, Aijun, et al. (2011). Preparation Of An Anhydrous Reverse Micelle Delivery System To Enhance Oral Bioavailability And Anti-Diabetic Efficacy Of Berberine European Journal Of Pharmaceutical Sciences 44, 1-2.
  56. ^ Tan, Xiang-Shan; Ma, Jing-Yi; Feng, Ru; Ma, Chao; Chen, Wen-Jing; Sun, Yu-Peng, et al. (2013). Tissue Distribution Of Berberine And Its Metabolites After Oral Administration In Rats Plos One 8, 10.
  57. ^ Chen, Yangchao; Feng, Ru; Shou, Jia-Wen; Zhao, Zhen-Xiong; He, Chi-Yu; Ma, Chao, et al. (2015). Transforming Berberine Into Its Intestine-Absorbable Form By The Gut Microbiota Scientific Reports 5, 1.
  58. ^ Fan, Yong; Alolga, Raphael N.; Chen, Zhuo; Liu, Li-Wei; Zhao, Yi-Jing; Li, Jin, et al. (2016). Significant Pharmacokinetic Differences Of Berberine Are Attributable To Variations In Gut Microbiota Between Africans And Chinese Scientific Reports 6, 1.
  59. ^ Wang, Yugang; Hua, Lei; Hu, Jun; Li, Lele; Lei, Fan; Du, Lijun, et al. (2010). Acute Toxicity Of Berberine And Its Correlation With The Blood Concentration In Mice Food And Chemical Toxicology 48, 4.
  60. ^ Pang, Bing; Zhao, Lin-Hua; Zhou, Qiang; Zhao, Tian-Yu; Wang, Han; Gu, Cheng-Juan, et al. (2015). Application Of Berberine On Treating Type 2 Diabetes Mellitus International Journal Of Endocrinology 2015, .
  61. ^ Yin, Jun; Xing, Huili; Ye, Jianping (2008). Efficacy Of Berberine In Patients With Type 2 Diabetes Mellitus Metabolism 57, 5.
  62. ^ Zhou, Yanmi; He, Ping; Liu, Aiming; Zhang, Lixin; Liu, Yunde; Dai, Renke (2011). Drug-drug Interactions Between Ketoconazole And Berberine In Rats: Pharmacokinetic Effects Benefit Pharmacodynamic Synergism Phytotherapy Research 26, 5.
  63. ^ Wu, Xiaochun; Li, Qing; Xin, Huawen; Yu, Airong; Zhong, Mingyuan (2005). Effects Of Berberine On The Blood Concentration Of Cyclosporin A In Renal Transplanted Recipients: Clinical And Pharmacokinetic Study European Journal Of Clinical Pharmacology 61, 8.
  64. ^ Qiu, W.; Jiang, X. H.; Liu, C. X.; Ju, Y.; Jin, J. X. (2009). Effect Of Berberine On The Pharmacokinetics Of Substrates Of CYP3A And P-gp Phytotherapy Research 23, 11.
  65. ^ Domitrović, Robert; Cvijanović, Olga; Pernjak-Pugel, Ester; Škoda, Marko; Mikelić, Lorena; Crnčević-Orlić, Željka (2013). Berberine Exerts Nephroprotective Effect Against Cisplatin-Induced Kidney Damage Through Inhibition Of Oxidative/Nitrosative Stress, Inflammation, Autophagy And Apoptosis Food And Chemical Toxicology 62, .
  66. ^ Germoush, Mousa O.; Soliman, Ayman S.; Mahmoud, Ayman (2014). Berberine Attenuates Isoniazid-Induced Hepatotoxicity By Modulating Peroxisome Proliferator-Activated Receptor Γ, Oxidative Stress And Inflammation International Journal Of Pharmacology 10, 8.
  67. ^ Sudhandiran, Ganapasam; Chitra, Palanivel; Saiprasad, Gowrikumar; Manikandan, Ramar (2013). Berberine Attenuates Bleomycin Induced Pulmonary Toxicity And Fibrosis Via Suppressing NF-κB Dependant TGF-β Activation: A Biphasic Experimental Study Toxicology Letters 219, 2.
  68. ^ Lv, Xiuxiu; Yu, Xiaohui; Wang, Yiyang; Wang, Faqiang; Li, Hongmei; Wang, Yanping, et al. (2012). Berberine Inhibits Doxorubicin-Triggered Cardiomyocyte Apoptosis Via Attenuating Mitochondrial Dysfunction And Increasing Bcl-2 Expression Plos One 7, 10.

Topics related to Aging

view all
  • Epigenetic aging clocks
    Epigenetic clocks are predictors of biological age based on alterations in an individual's DNA methylation profile.
  • Sirtuins
    Sirtuins play a key role in healthspan and longevity by regulating a variety of metabolic processes implicated in aging.
  • Sauna
    Sauna use exposes the body to extreme heat and, in turn, induces protective responses that improve health and may increase healthspan.
  • Brain-derived neurotrophic factor (BDNF)
    BDNF is a growth factor known for its influence on neuronal health and for its role in mediating the beneficial cognitive effects associated with exercise.
  • Metformin
    Metformin, a drug commonly used to treat type 2 diabetes, may modulate certain aging processes.
  • Toll-like receptors
    Toll-like receptors are a family of pattern recognition receptors expressed on the surface of immune and other cells that play an important role in intestinal permeability and inflammaging.